The phase III IMpower110 trial recruited previously untreated individuals with nonsquamous or squamous stage IV non-small-cell lung cancer (NSCLC) with a view to comparing single-agent atezolizumab versus chemotherapy with cisplatin or carboplatin plus pemetrexed or gemcitabine.
The interim overall survival analysis will be presented at the ESMO Congress 2019:
IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
Friday, 27 September: 16:39–16:51 (Abstract LBA78)
Presenter: David Spigel, Sarah Cannon Research Institute, Nashville, Tennessee, USA